PUBLIC CONTRACT · 2022
Pc 2022120029 1567622, blinatumomab 38.5 ug po conc sol inj fr IV
- Contract value
- €59,108.28
- Signed on
- 9 December 2022
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9796230PUBLISHED SUBJECT
PC 2022120029 1567622, BLINATUMOMAB 38.5 UG PO CONC SOL INJ FR IV
Parties involved
- Place of performance
- Portugal, Porto, Porto
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- AMGEN BIOFARMACEUTICA, LDA · Tax ID 502942959
Values and timeline
- Contract price
- €59,108.28
- Procedure base price
- €59,108.28
- Total effective price
- Not reported on Portal BASE
- Publication date
- 11 February 2023
- Award date
- 9 December 2022
- Signing date
- 9 December 2022
- Performance period
- 20 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33000000-0 - Equipamento médico, medicamentos e produtos para cuidados pessoais
- Legal basis
- Artigo 24.º, n.º 1, alínea c) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 6339389
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.